Items Tagged ‘IDO1 inhibitor’

June 4th, 2014

Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients

By

In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well tolerated in metastatic melanoma patients and showed promising tumor response and duration of response. Adverse events previously observed with Yervoy were found to be reversible with proper management. IDO1 […]

View full entry

Tags: IDO1 inhibitor, INCB024360, ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Yervoy